Nuclear receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-18. Anything still debated is marked as such rather than presented as settled.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Delivery of oral high-dose supplements remains the principal strategy for minimizing deficiency. As of 2017, more than 80 countries worldwide are implementing universal VAS programs targeted to children 6–59 months of age through semi-annual national campaigns. Doses in these programs are one dose of 50,000 or 100,000 IU for children aged 6 to 11 months and 100,000 to 200,000 IU for children aged 12 months to five years, every four to six months.
== Evolutionary diversity == Most mammals have MHC variants similar to those of humans, who bear great allelic diversity, especially among the nine classical genes—seemingly due largely to gene duplication—though human MHC regions have many pseudogenes. The most diverse loci, namely HLA-A, HLA-B, and HLA-C, have roughly 6000, 7200, and 5800 known alleles, respectively. Many HLA alleles are ancient, sometimes of closer homology to a chimpanzee MHC alleles than to some other human alleles of the same gene. MHC allelic diversity has challenged evolutionary biologists for explanation. Most posit balancing selection (see polymorphism (biology)), which is any natural selection process whereby no single allele is absolutely most fit, such as frequency-dependent selection and heterozygote advantage. Pathogenic coevolution, as a type of balancing selection, posits that common alleles are under greatest pathogenic pressure, driving positive selection of uncommon alleles—moving targets, so to say, for pathogens. As pathogenic pressure on the previously common alleles decreases, their frequency in the population stabilizes, and remain circulating in a large population. Genetic drift is also a major driving force in some species. It is possible that the combined effects of some or all of these factors cause the genetic diversity. Beyond allelic polymorphism, the degree of evolutionary divergence between MHC alleles within individuals also influences immune function.
In 1997, Mahathir strongly supported Myanmar's inclusion into ASEAN, stating that "we are going to work very hard to get Burma into ASEAN" despite international criticism and American sanctions against the military regime. Mahathir presided as ASEAN chair over Myanmar's admission, playing a key role in ensuring its membership. However, by 2003, Mahathir's stance toward Myanmar had shifted significantly, particularly following the prolonged detention of pro-democracy leader Aung San Suu Kyi. In an interview, he openly stated that if Myanmar's military government continued to refuse Suu Kyi's release, ASEAN might have to consider expelling the country. This marked the first time an ASEAN leader had raised the possibility of Myanmar's expulsion, drawing considerable international attention.
== Legality == Plant breeding is subject to a different set of rules and regulations, at times contradictory. The International Union for the Protection of New Varieties of Plants (UPOV Convention) grants limited proprietary rights to breeders over their seeds, under certain conditions. In parallel, and often in a conflicting way, a series of dispositions aiming to fight against biopiracy require breeders to prove that the free, prior and informed consent was obtained from the communities (often Indigenous peoples or peasant communities) from where the seeds used to breed the new variety originates. This is the case in particular of the Nagoya Protocol, a treaty complementing the Convention on Biological Diversity, in force since 2014 (2017 in the European Union). In 2024, the GRATK Treaty was adopted, preventing national patent offices from granting patents based on biopiracy. Patent applicants relying on Cannabis strains will have to disclose the origin of the variety, which often entails compliance under the Nagoya protocol or other similar mechanisms of Access and Benefit Sharing Agreement.
Sources: en.wikipedia.org
For example, in RWE AG v Verbraucherzentrale NRW eV clauses in gas supply contracts enabling corporation, RWE, to unilaterally vary prices were advised by the Court of Justice to be not sufficiently transparent, and therefore unfair. In Brusse v Jahani BV the Court of Justice advised that clauses in a tenancy contract requiring tenants pay €25 per day were likely unfair, and would have to be entirely void without replacement, if they were not substituted with more precise mandatory terms in national legislation. In Aziz v Caixa d'Estalvis de Catalunya, following the 2008 financial crisis, the European Court of Justice advised that even terms regarding repossession of homes in Spain had to be assessed for fairness by national courts. In Kušionová v SMART Capital a.s., the Court of Justice held that consumer law was to be interpreted in the light of fundamental rights, including the right to housing, if a home could be repossessed. Because consumer law operates through Directives, national courts have the final say on applying the general principles set out by the Court of Justice's case law.
===== Aerial transport ===== Despite normally being categorized as centre-left, the Lula government continued with the privatization of elements of the Brazilian infrastructure, such as in May 2023, when it carried out the auction of the Natal International Airport through its Ministry of Ports and Airports, which resulted in the purchase of this airfield by the Swiss state-owned company Flughafen Zürich AG (Zurich Airport Ltd.) By decision of the Ministry of Ports and Airports, in August 2023, flights arriving and departing from Santos Dumont airport were restricted from 2024, which could only occur with origin or destination up to 400 kilometers away. it limited, in practice, flights from the airport between Rio de Janeiro, São Paulo and Belo Horizonte; the measure sought to divert part of the flights to the Galeão International Airport, managed by the company RIOgaleão, controlled by the Changi Group, from Singapore; however, the decision was revised in November, exchanging the distance restriction for a restriction on passenger volume, which will be limited to 6.5 million per year.
=== Phase 3 === Brenipatide (LY-3537031) – glucagon-like peptide-1 (GLP-1) receptor agonist, gastric inhibitory polypeptide (GIP) receptor agonist – alcoholism Ketamine (AWKN-001; AWKN-P-001) – ionotropic glutamate NMDA receptor antagonist and dissociative hallucinogen – alcoholism Naloxone intranasal (FMXIN-001; NS-001; naloxone microspheres powder nasal spray) – μ-opioid receptor antagonist – opioid-related disorders Ondansetron (AD-04) – serotonin 5-HT3 receptor antagonist – alcoholism Zolpidem (ALM-006; ALM006) – GABAA receptor positive allosteric modulator/nonbenzodiazepine – substance-related disorders
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.